

Supplementary Fig. 1. Normalized dose-response of STAT1 phosphorylation in HeLa cells treated with IFN $\alpha$  2a-EGF chimeras and IFN $\alpha$  2a proteins. These data represent an independent replication of the experiment shown in Figure 3, using a wider range of protein concentrations. HeLa cells were incubated with vehicle (PBS), recombinant human IFN $\alpha$ -A (1.5 nM), recombinant human EGF (17 nM), IFN $\alpha$  2a-EGF chimera, and the corresponding wild-type and mutant IFN $\alpha$  2a proteins expressed in *Pichia*, and STAT1 Tyr701 phosphorylation was assayed as described in Figure 3 and in the Experimental Procedures. The bar graph at the top of the figure represents the normalization of densitometry scans of the immunoblot representing STAT1 phosphorylation to the immunoblot representing total actin (bottom). Densitometry was performed using AlphaEasy FC software.

Supplementary Fig. 2. EGF-responsiveness of an engineered, stable Daudi-EGFR cell line. Daudi cells that stably express EGFR were generated by retroviral transduction as described in the Experimental Procedures. Parental Daudi and Daudi-EGFR cells were treated with EGF for 5 minutes at 37 °C, and then assayed for total EGFR using the mouse antibody EGFR.1 (left panel) or for phospho-EGFR using a rabbit antiserum specific for pTyr1068 (right panel). From left to right, lanes are: M, molecular weight markers in kiloDaltons as indicated; parental Daudi cells vehicle or EGF; and Daudi cells transduced with pLPCX-EGFR as described in Experimental Procedures.





## Supplementary Fig 2.

